US Patent

US9616028 — Bilayer tablet formulations

Formulation · Assigned to AstraZeneca UK Ltd · Expires 2030-11-12 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects bilayer tablet formulations that combine metformin extended release with an SGLT2 inhibitor, such as Farxiga.

USPTO Abstract

The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.

Drugs covered by this patent

Patent Metadata

Patent number
US9616028
Jurisdiction
US
Classification
Formulation
Expires
2030-11-12
Drug substance claim
No
Drug product claim
Yes
Assignee
AstraZeneca UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.